It took them long enough, but the scientific community is finally acknowledging the "revolving door" that exists between the United States' Food and Drug Administration (FDA) and the pharmaceutical industry.
It is routine practice for high-level officials at the FDA to leave the agency and take lucrative positions within Big Pharma, explains a new investigatory report published in the British Medical Journal (BMJ).
The conflicts of interest with such an arrangement are endless, but they have never stopped this revolving door from spinning. Internal emails clearly show that FDA staff leave the agency to work at Big Pharma – and on their way out the door, they are given instructions about how to still peddle control from their new careers in the private drug and vaccine sector.
Freedom of Information Act (FOIA) requests produced emails to show how the FDA actually gives these outgoing employees a guidance explaining how they can work "behind the scenes" to run the FDA despite the fact that such post-employment lobbying may be illegal.
"The FDA's ethics staff proactively informed these departing employees that although U.S. law prohibits certain types of lobbying contact 'they do not prohibit the former employee from other activities, including working 'behind the scenes,'" reported The Exposé (United Kingdom).
(Related: The FDA knew all along about Wuhan coronavirus [COVID-19] "vaccine" shedding but withheld this deadly truth from the American public.)
FDA advises outgoing employees to break the law
One of the names revealed in the probe is Doran Fink, a former FDA employee who worked at the agency for more than 12 years as a physician-scientist. During the COVID "pandemic," Fink reviewed the so-called "vaccines." After the "pandemic" was over, Fink moved on to work at Moderna, the very company whose chemical injections he reviewed for emergency use authorization (EUA).
As for the restrictions that were applied to Fink upon his departure from the FDA, emails obtained by the BMJ through FOIA show that they were specifically "tailored to your situation." Though illegal, the FDA's ethics department told Fink that "they do not prohibit the former employee from other activities, including working 'behind the scenes.'"
Craig Holman, a government affairs lobbyist for the organization Public Citizen, told the BMJ that a "critical, critical loophole" exists in the U.S. as it pertains to revolving door policies.
"They can even run a lobbying campaign, as long as they don't actually pick up the telephone and make the contact with their former officials – and that's exactly the advice that's being given here," Holman said.
Another former FDA officer by the name of Jaya Goswami was reportedly given the same advice as Fink on her way out the door. Just like Fink, Goswami reviewed Moderna's mRNA COVID injection before conveniently leaving and going to work for Big Pharma.
In trying to justify the errant advice being dispensed by the FDA's ethics department, Center for Science in the Public Interest (CSPI) head Peter Lurie revealed that "it does seem contrary to the public interest that an ex-official would be quarterbacking activities behind the scenes, especially for a 'particular matter' on which they had worked," which is clearly what has been happening at the FDA for many years.
Peter Doshi, BMJ's senior editor, is credited with putting together the eye-opening report. The fact that it was even published at all shows just how much progress has been made in recent years to get the truth out via reputable sources.
It was not that long ago when talking about the FDA's revolving door was reserved mostly to conspiracy websites. To see something like this published in the BMJ is somewhat historic if you really think about.
The latest news about the highly corrupt FDA can be found at FDA.news.
Sources for this article include:
Please contact us for more information.